PLXNB1: A Potential Drug Target and Biomarker (G5364)

Target Name: PLXNB1

NCBI ID: G5364

PLXNB1

PLXNB1: A Potential Drug Target and Biomarker

PLXNB1, also known as P2RX, is a protein that is expressed in the brain and has been shown to play a role in pain perception and neurodegenerative diseases. The protein is a potential drug target and biomarker for a variety of therapeutic approaches.

The discovery of PLXNB1 as a potential drug target comes from a study by the neuroimaging center at the University of California, San Francisco. The study, published in the journal Neuron, used functional magnetic resonance imaging (fMRI) to identify that PLXNB1 was highly expressed in the brains of individuals with chronic pain and was associated with reduced pain sensitivity.

The team that conducted the study also found that individuals with chronic pain had reduced activity in the primary somatosensory cortical region of the brain, which is responsible for processing pain signals. This reduced activity in this region was associated with increased activity in the prefrontal cortex, which is responsible for executive function and decision-making.

These findings suggest that PLXNB1 may be a promising drug target for chronic pain. PLXNB1 is a potential drug target for chronic pain, as it is expressed in the brain and is associated with reduced pain sensitivity in individuals with chronic pain, said lead author Dr. Xinran Li, a researcher at the University of California, San Francisco.

PLXNB1 is also a potential biomarker for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and are associated with increased levels of PLXNB1 in the brain.

The study by Li and her team also found that individuals with Alzheimer's disease had increased levels of PLXNB1 in their brains, and that individuals with Parkinson's disease had reduced levels of PLXNB1 in their brains. These findings suggest that PLXNB1 may be a useful biomarker for these conditions.

In addition to its potential drug and biomarker applications, PLXNB1 is also a potential therapeutic target for pain and neurodegenerative diseases. The protein has been shown to play a role in the regulation of pain signaling and has been shown to interact with a variety of molecules, including GABA, a neurotransmitter that is involved in pain modulation.

The team that conducted the study also found that PLXNB1 is involved in the regulation of glutamate, a neurotransmitter that is involved in learning and memory. This suggests that PLXNB1 may be a useful target for the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

In conclusion, PLXNB1 is a protein that is expressed in the brain and has been shown to play a role in pain perception and neurodegenerative diseases. The protein is a potential drug target and biomarker for a variety of therapeutic approaches, including the treatment of chronic pain and neurodegenerative diseases. Further research is needed to fully understand the role of PLXNB1 in these conditions and to develop effective treatments.

Protein Name: Plexin B1

Functions: Receptor for SEMA4D (PubMed:19843518, PubMed:20877282, PubMed:21912513). Plays a role in GABAergic synapse development (By similarity). Mediates SEMA4A- and SEMA4D-dependent inhibitory synapse development (By similarity). Plays a role in RHOA activation and subsequent changes of the actin cytoskeleton (PubMed:12196628, PubMed:15210733). Plays a role in axon guidance, invasive growth and cell migration (PubMed:12198496)

The "PLXNB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLXNB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets